Fierce Pharma: Medicare Part D rule change would be another win for pharma’s lobbyists, analyst says

Fierce Pharma: Medicare Part D rule change would be another win for pharma’s lobbyists, analyst says

PCMA said a change to force insurance plans to “estimate and apply” manufacturer rebates at the point of sale would raise premiums by $28 billion